Real-World data shows Mavacamten's impact on heart condition

NCT ID NCT07168655

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study looked at 163 patients with obstructive hypertrophic cardiomyopathy who were prescribed mavacamten at a single US hospital. Researchers collected information on symptoms, heart function, and patient characteristics from medical records. The goal was to see how the drug performs outside of controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mavacamten
What this could lead to: If results are positive, this could confirm that mavacamten is effective and safe for a broad range of patients with obstructive hypertrophic cardiomyopathy in real-world settings.
What could go wrong: This is a small, single-center, completed study without a control group, so results may not apply to all patients. It only describes outcomes, not proving cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)

Contacts and locations

Locations

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.